Research programme: anti-inflammatory therapeutics - Janssen Biotech/Vectura
Alternative Names: anti-inflammatory therapeutics - Janssen Biotech/VecturaLatest Information Update: 28 Feb 2019
At a glance
- Originator Janssen Biotech; Vectura
- Developer Vectura
- Class Anti-inflammatories
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Asthma in United Kingdom (Inhalation, Powder)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation, Powder)
- 06 Jan 2015 Preclinical trials in Asthma in United Kingdom (Inhalation)